ChemoCentryx (NASDAQ: CCXI)
Some price data may be temporarily unavailable.
ChemoCentryx Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ChemoCentryx Company Info
ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
News & Analysis
Why ChemoCentryx Stock Is On Fire Today
The rare-disease specialist is being bought out at a sizable premium.
2 Stocks Down 30% in 2022 That Are Great Buys Right Now
Years from now you could be thanking yourself for buying shares of these two companies today.
Why ChemoCentryx Stock Tanked in 2021
A long, drawn out regulatory review weighed on the drugmaker's shares last year.
Is It Too Late to Buy ChemoCentryx Stock?
The stock surged after obtaining FDA approval for avacopan.
Why ChemoCentryx Stock Skyrocketed Today
Investors are excited about the biotech's game-changing new drug.
ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
The broader market was mixed on Friday.
2 Growth Stocks That Could Take Off Before the End of the Year
They've been struggling thus far in 2021, but things could turn around quickly for these companies.
Is Now the Time to Buy ChemoCentryx Stock?
Analysts following this risky biotech stock have changed their tune.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.